{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:20:41Z","timestamp":1790036441797,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejphar.2014.01.040","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T02:45:45Z","timestamp":1391136345000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":178,"special_numbering":"C","title":["SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats"],"prefix":"10.1016","volume":"727","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-2452","authenticated-orcid":false,"given":"Masanori","family":"Yokono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hayashizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Mitsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sousuke","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Sasamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.01.040_bib1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.metabol.2008.06.017","article-title":"Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats","volume":"57","author":"Alemzadeh","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2014.01.040_bib2","first-page":"BR439","article-title":"Diazoxide attenuates insulin secretion and hepatic lipogenesis in Zucker diabetic fatty rats","volume":"11","author":"Alemzadeh","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejphar.2014.01.040_bib3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2014.01.040_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1463-1326.2009.01182.x","article-title":"Diabesity: therapeutic options","volume":"12","author":"Colagiuri","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2014.01.040_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11906-009-0036-3","article-title":"The role of the sympathetic nervous system in obesity-related hypertension","volume":"11","author":"da Silva","year":"2009","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2014.01.040_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease: an update","volume":"126","author":"Despres","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2014.01.040_bib7","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2014.01.040_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00251010","article-title":"The effect of diazoxide-induced hormonal secretion on plasma triglyceride concentration in the rat","volume":"18","author":"Eaton","year":"1980","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2014.01.040_bib9","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.2337\/dc11-0447","article-title":"Obesity and type 2 diabetes: what can be unified and what needs to be individualized?","volume":"34","author":"Eckel","year":"2011","journal-title":"Diabetes Care"},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2014.01.040_bib10","first-page":"P428","article-title":"Validation of whole body DXA in young and adult rats","volume":"51","author":"Engelbregt","year":"1999","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejphar.2014.01.040_bib11","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2014.01.040_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12081","article-title":"A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes","volume":"15","author":"Ferrannini","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2014.01.040_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jdiacomp.2012.11.005","article-title":"Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus","volume":"27","author":"Fonseca","year":"2013","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.ejphar.2014.01.040_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1079\/PNS19800036","article-title":"Animal models for the study of energy balance","volume":"39","author":"Gurr","year":"1980","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.ejphar.2014.01.040_bib15","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/oby.2009.341","article-title":"Validation of computed tomographic estimates of intra-abdominal and subcutaneous adipose tissue in rats and mice","volume":"18","author":"Hillebrand","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2014.01.040_bib16","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.bmc.2012.03.051","article-title":"Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus","volume":"20","author":"Imamura","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2014.01.040_bib17","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.12149","article-title":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study","volume":"15","author":"Inagaki","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2014.01.040_bib18","doi-asserted-by":"crossref","first-page":"E1287","DOI":"10.1152\/ajpendo.90604.2008","article-title":"Metabolic cycling in control of glucose-stimulated insulin secretion","volume":"295","author":"Jensen","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2014.01.040_bib19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2014.01.040_bib20","first-page":"149","article-title":"Irpagliflozin improved glycemia control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study","volume":"54","author":"Kashiwagi","year":"2011","journal-title":"Diabetogogia"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2014.01.040_bib21","first-page":"A21","article-title":"ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes","volume":"59","author":"Kashiwagi","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2014.01.040_bib22","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2014.01.040_bib23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/ajcn\/47.4.608","article-title":"Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels","volume":"47","author":"Livesey","year":"1988","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ejphar.2014.01.040_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.medengphy.2008.03.006","article-title":"In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model","volume":"31","author":"Luu","year":"2009","journal-title":"Med. Eng. Phys."},{"key":"10.1016\/j.ejphar.2014.01.040_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1152\/physiol.00010.2007","article-title":"Brain glucose sensing, counterregulation, and energy homeostasis","volume":"22","author":"Marty","year":"2007","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.ejphar.2014.01.040_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2337\/db11-1050","article-title":"Brain glucose sensors play a significant role in the regulation of pancreatic glucose-stimulated insulin secretion","volume":"61","author":"Osundiji","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2014.01.040_bib27","doi-asserted-by":"crossref","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","article-title":"Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences","volume":"302","author":"Sabolic","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2014.01.040_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1089\/dia.2011.0012","article-title":"Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus","volume":"13","author":"Schwartz","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.ejphar.2014.01.040_bib29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.01.040_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1254\/jphs.12089FP","article-title":"Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin\u2013nicotinamide-induced mildly diabetic mice","volume":"120","author":"Tahara","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2014.01.040_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn-Schmiedeberg\u05f3s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.01.040_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/13813455.2010.535835","article-title":"Secreted proteins from adipose tissue and skeletal muscle\u2014adipokines, myokines and adipose\/muscle cross-talk","volume":"117","author":"Trayhurn","year":"2011","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2014.01.040_bib33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diab.44.8.863","article-title":"Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications","volume":"44","author":"Unger","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2014.01.040_bib34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2014.01.040_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00439-002-0820-5","article-title":"Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)","volume":"111","author":"van den Heuvel","year":"2002","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ejphar.2014.01.040_bib36","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium\u2013glucose cotransporter","volume":"263","author":"Wells","year":"1992","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2014.01.040_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12038","article-title":"Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study","volume":"15","author":"Wilding","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2014.01.040_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active sugar transport in health and disease","volume":"261","author":"Wright","year":"2007","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2014.01.040_bib39","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1463-1326.2010.01216.x","article-title":"Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes Obes. Metab."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T01:02:58Z","timestamp":1565139778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":39,"alternative-id":["S0014299914000703"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.040","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}